{"title":"Research progress on mRNA drug delivery strategies in the nervous system.","authors":"Bo Yang, Anqi Liu, Xiaojing Li, Zhigang Miao","doi":"10.1080/17435889.2025.2530242","DOIUrl":null,"url":null,"abstract":"<p><p>There has been little progress in the treatment of central nervous system (CNS) disorders in recent decades. To date, new therapeutic agents such as small molecule drugs, cytokines, monoclonal antibodies and vaccines targeting specific antigens are still in the research and development stage and have not yet entered clinical use. With the discovery of gene-editing technology and the development of new therapeutic strategies, mRNA has been developed and used as a new type of drug, showing potential application value in the treatment of various neurological diseases. However, mRNA drugs face difficulties in being delivered to the CNS to exert therapeutic effects. We conducted a review by searching the PubMed database for relevant literature up to now, focusing on the research progress of mRNA drug delivery systems in the nervous system and their applications in neurological diseases, explore the challenges and prospects of mRNA drugs in neurological diseases, and provide reference for the development and implementation of mRNA drugs for neurological diseases.</p>","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1-16"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2025.2530242","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
There has been little progress in the treatment of central nervous system (CNS) disorders in recent decades. To date, new therapeutic agents such as small molecule drugs, cytokines, monoclonal antibodies and vaccines targeting specific antigens are still in the research and development stage and have not yet entered clinical use. With the discovery of gene-editing technology and the development of new therapeutic strategies, mRNA has been developed and used as a new type of drug, showing potential application value in the treatment of various neurological diseases. However, mRNA drugs face difficulties in being delivered to the CNS to exert therapeutic effects. We conducted a review by searching the PubMed database for relevant literature up to now, focusing on the research progress of mRNA drug delivery systems in the nervous system and their applications in neurological diseases, explore the challenges and prospects of mRNA drugs in neurological diseases, and provide reference for the development and implementation of mRNA drugs for neurological diseases.